Expression of the PD-1 ligand PD-L1 in tumor tissue (tPD-L1) is the most well-established biomarker for treatment with antibodies to PD-1 or to PD-L1 in patients with advanced NSCLC. Here, PDCD1 is linked to neoplasm.